Search the Newsreel

AbbVie Defends Its Turf, But Leaves One Big Question Open

Photo by jarmoluk on Pixabay AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet. AbbVie (ABBV) is on a roll, with …

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory …

Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations …

Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation

Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the …

AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision …

AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in …

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% …

Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices

Updated program delivers simplified savings, greater benefits transparency, and expanded opportunities for practice growth Introduces new rewards opportunities for customer segments, including first-time APP members, growing practices, and long-standing loyal customers IRVINE, Calif., Aug. 11, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today …

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

AbbVie (NYSE: ABBV) is aiming high with its $10.6 billion planned purchase of Apogee Therapeutics (NASDAQ: APGE). The deal, pending regulatory approvals, is expected to close in the third quarter. The move is designed to supplement the pharmaceutical giant's already strong immunology portfolio. However, …

AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use

AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face …

The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie's Q2 Earnings Call AbbVie's second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable …

Análise e Previsão das Ações da AbbVie Inc (ABBV)

AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed

In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie …

Projeções de Resultados: AbbVie Inc (ABBV) — LPA e Crescimento de Receita

Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended into Q4 2027 on ...

This article first appeared on GuruFocus. Cash Position: Ended Q2 2026 with cash, equivalents, and marketable securities of $106 million. Pro Forma Cash: More than $310 million after receiving a $100 million milestone payment from AbbVie and approximately $108 million in net proceeds from …

Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Let's …

Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

AbbVie (ABBV) Wins FDA Review For BOTOX Cosmetic In Jawline Treatment Push

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Allergan Aesthetics, an AbbVie company, reported that the FDA has accepted for review a supplemental Biologics License Application for BOTOX Cosmetic to treat …

ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset

ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset Pharmaceutical company AbbVie (NYSE:ABBV) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share …

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

If approved, BOTOX®Cosmetic (onabotulinumtoxinA) would be the only neurotoxin with five aesthetic indications and the first and only approved for masseter muscle prominence in the U.S. Submission is supported by two Phase 3 studies (M21-416 and M21-417), demonstrating statistically significant improvements in masseter muscle …

UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment

UBRELVY®(ubrogepant) positive recommendation by Canada's Drug Agency (CDA-AMC)is supported by evidence from the pivotal Phase 3 ACHIEVE I and ACHIEVE II studies. CDA-AMC recommendation recognizes the need for additional migraine-specific acute treatment options for adults. Migraine affects an estimated 5 million Canadians with the …

Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026–2036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight

DelveInsight Business Research LLP The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates (ADCs), next-generation targeted therapies, and combination immunotherapy regimens. Emerging candidates such as Telisotuzumab adizutecan (AbbVie) highlight this progress by delivering …

AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says

AbbVie (ABBV) reported another "strong" quarter operationally, with investor attention increasingly PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

ABBV Q2 Earnings Call Balances Growth With Apogee Dilution

AbbVie Inc. ABBV paired strong product momentum with a more complex 2026 outlook. Management raised revenue expectations, while the planned Apogee Therapeutics acquisition pushed adjusted earnings guidance modestly lower. The call focused on Skyrizi, Rinvoq and neuroscience growth, the case for Apogee and a …

AbbVie (ABBV) Wins EU Approval For RINVOQ In Vitiligo And Alopecia

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. AbbVie (NYSE:ABBV) received European Commission approval for RINVOQ (upadacitinib) as the first systemic treatment in the EU for non segmental vitiligo. The decision also covers …

AbbVie Inc (ABBV) (Q2 2026) Earnings Call Highlights: Robust Growth Driven by Skyrizi and ...

This article first appeared on GuruFocus. Release Date: July 31, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbbVie Inc (NYSE:ABBV) delivered another excellent quarter with total net revenues of nearly $17 billion, …

AbbVie Earnings Beat Forecasts as Skyrizi Sales Soar 24%. Why the Stock Is Falling.

AbbVie slashes its full-year guidance to account for its pending acquisition of Apogee Therapeutics. Continue Reading

ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down

AbbVie ABBV reported second-quarter 2026 adjusted EPS of $3.65, which beat the Zacks Consensus Estimate of $3.64. The reported figure also exceeded the company's guidance of $3.57-$3.61 per share, issued earlier in July 2026. Earnings rose 22.9% year over year. ABBV's revenues of $16.99 …

AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition

AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

AbbVie Beats but Cuts Guidance on $10.9 Billion Acquisition

This article first appeared on GuruFocus. AbbVie (NYSE:ABBV) fell 3.46% premarket after trimming full-year guidance alongside second-quarter results that beat on both lines. Net revenues rose 10.2% to $16.99 billion against the $16.78 billion analysts expected, and adjusted diluted earnings of $3.65 a share …

AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2026, AbbVie (ABBV) reported revenue of $16.99 billion, up 10.2% over the same period last year. EPS came in at $3.65, compared to $2.97 in the year-ago quarter. The reported revenue represents a surprise of +1.07% over the Zacks …

AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue

AbbVie's (NYSE:ABBV) Q2 CY2026: Beats On Revenue Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts' consensus estimates. Is now …

AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates

AbbVie (ABBV) came out with quarterly earnings of $3.65 per share, beating the Zacks Consensus Estimate of $3.64 per share. This compares to earnings of $2.97 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …